Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Midostaurin
open-in-new
<p>Midostaurin, sold under the brand name Rydapt by <a href="/facts/Novartis/jDregKez">Novartis</a>, is a multi-targeted <a href="/facts/Protein_kinase_inhibitor/uG5lnQ3C">protein kinase inhibitor</a> that has been investigated for the treatment of <a href="/facts/Acute_myeloid_leukemia/jvbXzg3J">acute myeloid leukemia</a> (AML), <a href="/facts/Myelodysplastic_syndrome/6ppeUYWk">myelodysplastic syndrome</a> (MDS) and advanced <a href="/facts/Systemic_mastocytosis/BDzye3Ra">systemic mastocytosis</a>. It is a semi-synthetic derivative of <a href="/facts/Staurosporine/0IXu5c1P">staurosporine</a>, an <a href="/facts/Alkaloid/m6hUXohz">alkaloid</a> from the bacterium <i><a href="/facts/Streptomyces/xupjSFmJ">Streptomyces</a> staurosporeus</i>. </p><p>The US <a href="/facts/Food_and_Drug_Administration/rCEnh9WB">Food and Drug Administration</a> (FDA) considers it to be a <a href="/facts/First-in-class_medication/ksvbEbS4">first-in-class medication</a>. </p>